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OBJECTIVES This study was designed to determine the prevalence and clinical manifestations of 22q11.2
microdeletion in adults with selected conotruncal anomalies and to assess the clinician’s ability
to predict the presence or absence of 22q11.2 microdeletion on the basis of clinical features.
BACKGROUND It is known that 22q11.2 microdeletion is a chromosomal anomaly with cardiac and
extracardiac manifestations. The prevalence and manifestations in adults have not been well
characterized.
METHODS A total of 103 consecutive adults with either tetralogy of Fallot (TOF), pulmonary
atresia/ventricular septal defect (PA/VSD), or truncus arteriosus (TA) were prospectively
screened for 22q11.2 microdeletion using a fluorescence in situ hybridization (FISH) assay.
Clinicians were asked to predict 22q11.2 microdeletion status on the basis of clinical features.
A geneticist blinded to FISH assay results reviewed photographs of the patients for typical
dysmorphic features of 22q11.2 microdeletion.
RESULTS Six patients (prevalence 5.8%, 95% confidence interval 1.3 to 10.3) had 22q11.2 microdele-
tion (3 with TOF, 2 with PA/VSD, 1 with TA). In two of these patients, the clinician
incorrectly predicted absence of the deletion. In three, typical dysmorphic features of 22q11.2
microdeletion were absent.
CONCLUSIONS Our work showed that 22q11.2 microdeletion is under-recognized in adults with congenital
heart disease. The absence of typical phenotypic features makes it difficult to correctly predict
if the deletion is present. Screening for 22q11.2 microdeletion should be considered in adults
with high-risk cardiac lesions, as it has important implications in reproductive counseling and
surveillance for associated extracardiac manifestations. (J Am Coll Cardiol 2005;45:595–8)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.056© 2005 by the American College of Cardiology Foundation
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ahe 22q11.2 microdeletion syndrome is characterized by a
emizygous deletion that encompasses several genes on
hromosome 22q11.2. Mutation of the TBX1 gene has
ecently been suggested as a major determinant of the
yndrome (1). The deletion usually arises spontaneously and
s relatively common (1 in 4,000 to 6,000 live births) (2).
he 22q11.2 microdeletion is found in the majority of
atients with DiGeorge syndrome and velocardiofacial and
onotruncal anomaly face syndromes, suggesting that these
yndromes represent a spectrum of phenotypic expression of
he deletion (3). Typically, the associated cardiac anomalies
nvolve the conotruncus and include lesions such as tetralogy
f Fallot (TOF), pulmonary atresia/ventricular septal defect
PA/VSD), and truncus arteriosus (TA) (3). The purpose of
his study was to determine the prevalence and clinical
anifestations of 22q11.2 microdeletion in adults with
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anada; †Division of Cardiovascular Diseases and Internal Medicine, ‡Division of
aboratory Genetics and the §Department of Medical Genetics, Mayo Clinic,
ochester, Minnesota.c
Manuscript received June 21, 2004; revised manuscript received September 29,
004, accepted October 26, 2004.elected conotruncal anomalies and to assess the ability of
linicians to predict the presence of 22q11.2 microdeletion.
ETHODS
rom October 2001 to September 2003, all patients with
OF, PA/VSD, or TA who had prescheduled appoint-
ents in the adult congenital heart disease clinic at the
ayo Clinic were identified. At the time of routine diag-
ostic venipuncture, an extra 5 ml of blood was drawn and
ent for cytogenetic analysis only after consent from the
atient was obtained. The study was approved by the Mayo
linic Institutional Review Board.
ISH. Fluorescence in situ hybridization (FISH) was per-
ormed with a critical region probe for the DiGeorge/
elocardiofacial syndrome chromosome region (Vysis probe
et for TUPLE-1) of chromosome 22 (22q11.2) (4).
linical evaluation. During the clinic visit a questionnaire
as conducted. Photographs of frontal and lateral facial
iews and both hands were taken. The clinician was asked to
redict 22q11.2 microdeletion status on the basis of the
vailable clinical information and physical features; the
linician was blinded to the results of the FISH analysis. A
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22q11.2 Microdeletion in ACHD February 15, 2005:595–8eneticist blinded both to the FISH results and clinical
eatures independently reviewed the patient’s photographs
o determine the presence of the typical dysmorphic features
f 22q11.2 microdeletion. Patients were offered the oppor-
unity to learn their test results, at which time counseling by
physician was provided. Patients with the deletion were
eferred to medical genetics for further assessment and
ounseling.
ESULTS
ohort. A total of 104 consecutive patients were offered
creening. One patient declined; this patient did not have
eatures to suggest 22q11.2 microdeletion. Thereafter, 103
atients underwent testing with FISH analysis (mean age
0  12 years, range 18 to 70 years). The intracardiac
iagnoses consisted of TOF in 77 patients, PA/VSD in 23,
nd TA in 3.
atients with 22q11.2 deletion. Six patients (5.8%, 95%
onfidence interval [CI] 1.3 to 10.3) were found to have a
2q11.2 microdeletion (Tables 1 and 2). The prevalence for
ach diagnosis was TOF 3.8% (95% CI 0 to 8.2), PA/VSD
.7% (95% CI 0 to 20.2), TA 33.3% (95% CI 0 to 86.7).
wo patients had children. Patient #1 had a healthy female
hild without 22q11.2 microdeletion. Patient #3 had a
emale child with 22q11.2 microdeletion and truncus
rteriosus.
linical prediction and presence of dysmorphic features. In
wo of the patients with 22q11.2 microdeletion, the clini-
ian incorrectly predicted absence of the microdeletion. The
2q11.2 microdeletion was predicted in nine patients who
ere found to be negative on FISH analysis (Table 3). Of
he 103 patients, 93 agreed to have their photographs taken.
hree of the six FISH-positive patients were found by the
eneticist to have typical dysmorphic features of 22q11.2
icrodeletion on the basis of the photographs; five FISH-
Abbreviations and Acronyms
CI  confidence interval
FISH  fluorescence in situ hybridization
PA/VSD  pulmonary atresia/ventricular septal defect
TA  truncus arteriosus
TOF  tetralogy of Fallot
Table 1. Cardiac Manifestations of Patients W
Patient Age, Gender Anatomy
Pulmon
Arter
1 26, F TOF H and
2 25, F TOF Normal
3 47, M TOF Normal
4 26, F PA/VSD H and
5 32, F PA/VSD H and
6 27, F TA Normal
C  confluent; H  hypoplastic; MAPCAs  major aort
pulmonary atresia/ventricular septal defect; RAIV  retro-aortic
artery; TA  truncus arteriosus; TOF  tetralogy of Fallot.egative patients had typical or suggestive dysmorphism of
2q11.2 on the basis of the photographs.
ISCUSSION
he prevalence of 22q11.2 microdeletion found in our study
or each cardiac anomaly was lower than what has been
eported in published pediatric reports (TOF 6% to 21%,
A/VSD 32% to 48%) (5–8). This discrepancy between
hildren and adults may possibly be explained by a higher
ttrition rate in children with 22q11.2 microdeletion. In-
eed, reports have indicated that for PA/VSD, 22q11.2
icrodeletion patients have a tendency to have more com-
lex pulmonary artery anatomy when compared with the
2q11.2 microdeletion-negative patients (6,7,9). This may
nfavorably affect surgical and percutaneous interventions
nd long-term outcome. Furthermore, extracardiac compli-
ations associated with 22q11.2 microdeletion may affect
urvival into adulthood (10).
There are few reports that have characterized the adult
henotype of 22q11.2 microdeletion (11–13). There is a
uggestion that adults with 22q11.2 microdeletion may have
igher rates of learning disabilities, psychiatric disorders,
nd palate anomalies, but lower rates of congenital heart
isease when compared to children (12). However, the
ajority of adults reported previously were ascertained
ollowing diagnosis of affected offspring, which may have
ntroduced bias (12).
The ability of the clinician to predict 22q11.2 microde-
etion based on the presence of typical clinical features was
ifficult. The clinicians both erred in missing and overdiag-
osing 22q11.2 microdeletion. These clinicians were experts
n adult congenital heart disease, but specific training for the
tudy was not given. Although reports have shown that
ost 22q11.2 microdeletion patients have at least one
xtracardiac manifestation that is typical of the microdele-
ion (14), two of our patients had none. Even though it is
ossible, therefore, that more extensive education regarding
he typical features of 22q11.2 microdeletion may have
ncreased the accuracy of the physicians’ predictions, the
hallenges of accurate clinical diagnosis are evident.
The poor correlation between the presence of typical
ysmorphic features and 22q11.2 microdeletion can be
xplained by several possible factors. The assessment of
2q11.2 Microdeletion (n  6)
MAPCAs Arch Side Arch Vessels
N Right Normal
N Right Normal
N Left Normal
Y Left Normal
Y Left RLSA and RAIV
N Left Normal
onary collateral arteries; NC  nonconfluent; PA/VSD ith 2
ary
y
C
C
NC
opulm
innominate vein; RLSA  retro-esophageal left subclavian
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February 15, 2005:595–8 22q11.2 Microdeletion in ACHDypical dysmorphic features by the geneticist was based
olely on review of the photographs. Also, aging changes or
bscuring of features may have been a factor. As for patients
ho were felt to have typical features but not found to have
22q11.2 microdeletion, this highlights the difficulties for
ven the most experienced physician in recognizing the
yndrome.
linical relevance. Although the 22q11.2 microdeletion is
ow well described in the pediatric literature, our data
uggest there are likely many adults with unrecognized
2q11.2 microdeletion who are followed in adult congenital
eart disease clinics. This may be partly explained by the
nly recent availability of the FISH probe, so that the
ajority of adults who are presently followed in adult
ongenital heart disease clinics did not have access to testing
t the time when they were under the care of pediatricians
15). Lack of awareness of the clinical features and avail-
bility of testing for 22q11.2 microdeletion syndrome may
lso contribute. Furthermore, our results indicate that
2q11.2 microdeletion may be difficult to detect in the adult
opulation, even by cardiologists with expertise in congen-
tal heart disease.
It is reasonable to postulate that the identification of
2q11.2 microdeletion in the pediatric and adult population
ost likely optimizes the recognition and management of
ts extracardiac complications (12). Furthermore, an impor-
ant issue unique to the adult population is counseling
egarding reproduction. Children born to a parent with
2q11.2 microdeletion have a 50% chance of having the
eletion themselves, as well as its associated complications
16). This has become even more relevant now that prenatal
esting for 22q11.2 microdeletion has become available (16).
ypical features that should alert the clinician of possible
resence of 22q11.2 microdeletion in a patient with adult
ongenital heart disease. The cardiovascular abnormalities
hat have the highest reported prevalence of 22q11.2 are
isted in Table 4. Within the same cardiac diagnoses,
Table 2. Extracardiac Manifestations of Patien
Patient
Palatal
Anomalies
Speech
Difficulty
Calcium
Level
1 Cleft Y Normal
2 N N Normal
3 N N Normal
4 N N Normal
5 N N Normal
6 N N Normal
able 3. Ability of Clinician to Predict Presence of 22q11.2
icrodeletion Based on the Available Clinical Information and
hysical Features (n  103)
Clinically Predicted
to Be Positive
Clinically Predicted
to Be Negative
ISH positive 4 2
ISH negative 9 88ISH  fluorescence in situ hybridization.
I
datients with 22q11.2 microdeletion are reported to have a
igher incidence of right aortic arch, abnormal anatomy of
he great arteries, or abnormalities of the pulmonary arteries
3,17). Apart from the cardiac anomalies listed in Table 1,
ypical extracardiac anomalies that may alert the clinician to
nderlying 22q11.2 microdeletion are listed in Table 4.
lthough there is a large phenotypic variability, typical
acial features include a long narrow face with flat malar
ones, small chin, hooded eyelids, narrow palpebral fissures,
rectangular” nose that can be long with paranasal bossing
nd a squared or sometimes bulbous tip, small mouth, and
mall ears with overfolding of the superior helix (Fig. 1)
13). These facial features may be subtle in adults and some
an be associated with aging changes in normal individuals
13).
hich adults should be screened? This is a difficult and
ontroversial issue (3,18,19). We suggest that cardiologists
hould first consider the possibility of underlying 22q11.2
icrodeletion when assessing all patients with adult con-
enital heart disease, especially those with conotruncal
nomalies. Presence of high-risk cardiac lesions, or typical
ssociated cardiac and extracardiac anomalies, should
rompt consideration of screening and discussion with the
atient. The patient should be presented with the pros
screening for extracardiac manifestation, knowledge as to
he potential for transmission to offspring) and cons (insur-
nce accessibility) of screening and offered appropriate
enetic counseling. If found to be positive, the patient
ith 22q11.2 Microdeletion (n  6)
Learning
Disability
Psychiatric
History Other
N N N
Y Y N
N N Thrombocytopenia
N N N
N N N
Y N Hypocalcemia
able 4. Typical Clinical Features That Should Alert the
linician of Possible Presence of 22q11.2 Deletion
ommonly associated cardiovascular lesions
TOF
PA/VSD
TA
IAA (type B)
Isolated arch anomalies
xtracardiac manifestations
Psychiatric history
Mental retardation
Nonverbal learning disability
Dysmorphic facial features
History of cleft palate
Hypernasal speech
Hypocalcemiats WAA  interrupted aortic arch; PA/VSD  pulmonary atresia/ventricular septal
efect; TA  truncus arteriosus; TOF  tetralogy of Fallot.
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22q11.2 Microdeletion in ACHD February 15, 2005:595–8hould undergo investigations to screen for associated
nomalies.
tudy limitations. The relatively small number of patients
ith 22q11.2 microdeletion found in our study has pre-
ented us from making meaningful statements on: 1) the
henotype of the adult with 22q11.2 microdeletion; 2) the
resence of typical associations with each anatomical defect;
nd 3) differences between 22q11.2 microdeletion-positive
nd -negative patients who have conotruncal anomalies.
onclusions. The 22q11.2 microdeletion syndrome is
nder-recognized in patients with adult congenital heart
isease. It is difficult to determine if the deletion is present
r absent solely on the basis of an assessment on phenotypic
eatures. Screening for 22q11.2 microdeletion by FISH
igure 1. Facial views of two of the patients with 22q11.2 microdeletion
llustrating the spectrum of facial dysmorphism. (A) Patient #3 in text.
xcept for mild upper eyelid changes associated with normal aging, this
7-year-old man does not have typical dysmorphic changes of 22q11.2
icrodeletion. (B) Patient #6 in text. This 27-year-old woman has facial
eatures of 22q11.2 microdeletion including a long face, paranasal bossing,
nd hooded appearance of the upper eyelids with narrow palpebral fissures.nalysis should be considered in adult patients with high-isk cardiac lesions, as there are important counseling
mplications for reproduction and surveillance for associated
xtracardiac manifestations.
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